Clinical Trial Outcomes: Clinical trials are inherently risky, and the failure of any of Inflarx's product candidates to demonstrate safety and efficacy could lead to the discontinuation of development or significant delays, negatively impacting the company's prospects and stock value.

Regulatory Approval Hurdles: Inflarx's drug candidates must receive regulatory approval before they can be commercialized, and the failure to obtain or significant delays in obtaining such approvals could prevent or significantly delay product launches.

Intense Market Competition: The biopharmaceutical industry is highly competitive, and Inflarx's existing and future product candidates may be rendered obsolete or uncompetitive by products developed by competitors with greater resources or more effective therapies.